{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T03:55:44Z","timestamp":1795146944876,"version":"4.10.3"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To report on our experience using intravitreal methotrexate (MTX) in patients with retinal detachment associated with proliferative vitreoretinopathy and\/or open globe injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study performed a retrospective chart review of a consecutive series of 21 eyes of 21 patients who underwent serial intravitreal MTX injection for treatment and\/or prevention of proliferative vitreoretinopathy from December 2021 to January 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Twenty-one patients underwent pars plana vitrectomy, membrane peeling, laser photocoagulation, silicone oil infusion, and intravitreal MTX injection. Postoperatively, all eyes received a series of intravitreal MTX (400\n                      <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>\n                      g\/0.1 mL) injections. Optimally, injections were administered weekly for 8 weeks and every 2 weeks for four weeks for a total of 13 injections, beginning intraoperatively at the conclusion of retinal reattachment surgery. Mean baseline preoperative and postoperative visual acuity was logarithm of the minimum angle of resolution 3.2 (approximately hand motions vision) and 2.5 (between CF and hand motions vision), respectively, yielding an average improvement in visual acuity of 0.7 logarithm of the minimum angle of resolution units (0 ETDRS lines\/letters). These 21 patients received an average of 10.5 injections. With a single operation, detachments in 19 (90%) of 21 eyes were successfully reattached. Corneal epithelial defects were noted in 7 (33%) of 21 patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Serial intravitreal MTX injection was associated with 90% single operation retinal reattachment rate in the setting of retinal detachment with proliferative vitreoretinopathy or retinal detachment at high risk of proliferative vitreoretinopathy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004181","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T13:15:51Z","timestamp":1726578951000},"page":"1748-1757","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["INTRAVITREAL METHOTREXATE INJECTION FOR THE TREATMENT AND PREVENTION OF PROLIFERATIVE VITREORETINOPATHY"],"prefix":"10.1097","volume":"44","author":[{"given":"Patrick J.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelakshi","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1326-2782","authenticated-orcid":false,"given":"Orlando G.","family":"Gonzalez-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7811-7132","authenticated-orcid":false,"given":"Marco A.","family":"Zarbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250605","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0039-6257(98)00023-X","article-title":"Proliferative vitreoretinopathy: an overview","volume":"43","author":"Pastor","year":"1998","journal-title":"Surv Ophthalmol"},{"key":"R2-20250605","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1055\/s-0029-1245300","article-title":"Proliferative vitreoretinopathy\u2013pathogenesis and therapy [in German]","volume":"227","author":"Iandiev","year":"2010","journal-title":"Klin Monbl Augenheilkd"},{"key":"R3-20250605","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archopht.1989.01070020213027","article-title":"Clinical risk factors for proliferative vitreoretinopathy","volume":"107","author":"Cowley","year":"1989","journal-title":"Arch Ophthalmol"},{"key":"R4-20250605","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1167\/iovs.16-20912","article-title":"Effect of methotrexate on an in vitro patient-derived model of proliferative vitreoretinopathy","volume":"58","author":"Amarnani","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3109\/02713688409003063","article-title":"Effects of cytotoxic drugs on proliferative vitreoretinopathy in the rabbit cell injection model","volume":"3","author":"Sunalp","year":"1984","journal-title":"Curr Eye Res"},{"key":"R6-20250605","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.ophtha.2022.05.024","article-title":"Intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy: results from a randomized clinical trial","volume":"129","author":"Schaub","year":"2022","journal-title":"Ophthalmology"},{"key":"R7-20250605","doi-asserted-by":"crossref","first-page":"457","DOI":"10.18388\/abp.1995_4899","article-title":"Molecular mechanisms of resistance to antifolates, a review","volume":"42","author":"Banerjee","year":"1995","journal-title":"Acta Biochim Pol"},{"key":"R8-20250605","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":"Methotrexate for ocular inflammatory diseases","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology"},{"key":"R9-20250605","doi-asserted-by":"crossref","first-page":"e000293","DOI":"10.1136\/bmjophth-2019-000293","article-title":"Intravitreal methotrexate for the treatment of proliferative vitreoretinopathy","volume":"4","author":"Benner","year":"2019","journal-title":"BMJ Open Ophthalmol"},{"key":"R10-20250605","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3928\/23258160-20220920-04","article-title":"Intravitreal methotrexate for the prevention and treatment of proliferative vitreoretinopathy in rhegmatogenous retinal detachment: a systematic review","volume":"53","author":"Balas","year":"2022","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R11-20250605","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3928\/23258160-20230220-01","article-title":"Low-dose intravitreal methotrexate for proliferative vitreoretinopathy","volume":"54","author":"Ullah","year":"2023","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R12-20250605","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1007\/s00417-021-05206-z","article-title":"Adjunctive serial post-operative intravitreal methotrexate injections in the management of advanced proliferative vitreoretinopathy","volume":"259","author":"Roca","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R13-20250605","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000500271","article-title":"Repeated injection of methotrexate into silicone oil-filled eyes for Grade C proliferative vitreoretinopathy: a pilot study","volume":"242","author":"Nourinia","year":"2019","journal-title":"Ophthalmologica"},{"key":"R14-20250605","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/ICB.0000000000001252","article-title":"Rescue intravitreal methotrexate treatment following early recognition of proliferative vitreoretinopathy","volume":"17","author":"Alabi","year":"2023","journal-title":"Retin Cases Brief Rep"},{"key":"R15-20250605","article-title":"Methotrexate for proliferative vitreoretinopathy","author":"Eliott","journal-title":"Proceedings of the New England Ophthalmological Society 768th Meeting; March 9, 2018"},{"key":"R16-20250605","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3928\/1081-597X-19970701-16","article-title":"Proper method for calculating average visual acuity","volume":"13","author":"Holladay","year":"1997","journal-title":"J Refract Surg"},{"key":"R17-20250605","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0002-9394(14)76695-4","article-title":"An updated classification of retinal detachment with proliferative vitreoretinopathy","volume":"112","author":"Machemer","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"R19-20250605","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00417-015-3007-1","article-title":"Biodegradable chitosan and polylactic acid-based intraocular micro-implant for sustained release of methotrexate into vitreous: analysis of pharmacokinetics and toxicity in rabbit eyes","volume":"253","author":"Manna","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R20-20250605","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1097\/IAE.0b013e31828ac07d","article-title":"Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis","volume":"33","author":"Taylor","year":"2013","journal-title":"Retina"},{"key":"R21-20250605","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1097\/ICO.0b013e3182910106","article-title":"Toxic corneal epitheliopathy after intravitreal methotrexate and its treatment with oral folic acid","volume":"32","author":"Gorovoy","year":"2013","journal-title":"Cornea"},{"key":"R22-20250605","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/01.WNO.0000166061.73483.CE","article-title":"Reversible optic neuropathy associated with low-dose methotrexate therapy","volume":"25","author":"Clare","year":"2005","journal-title":"J Neuroophthalmol"},{"key":"R23-20250605","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2147\/OPTH.S111893","article-title":"Intravitreal methotrexate infusion for proliferative vitreoretinopathy","volume":"10","author":"Sadaka","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"R24-20250605","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye (Lond)"},{"key":"R25-20250605","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3390\/pharmaceutics13081227","article-title":"Pharmacokinetics and toxicity evaluation of a PLGA and chitosan-based micro-implant for sustained release of methotrexate in rabbit vitreous","volume":"13","author":"Manna","year":"2021","journal-title":"Pharmaceutics"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T13:02:31Z","timestamp":1749128551000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004181","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}